Showing papers in "Biology of Blood and Marrow Transplantation in 2009"

TL;DR: Changes include the recommendations for PCV rather than PPSV-23 for pneumococcal vaccination, starting some vaccinations earlier post-transplant, and the addition of recommendations for Varivax, HPV vaccine, and (the non-use of) Zostavax vaccine are included.

TL;DR: This report proposes to define conditioning regimens in 3 categories: (1) myeloablative (MA) conditioning, (2) reduced-intensity conditioning (RIC), and (3) nonmyeloablatives (NMA) Conditioning, based on the duration of cytopenia and on the requirement for stem cell support.

TL;DR: Although HCT professionals have not reached a consensus on what constitutes a RIC regimen, most accept currently used criteria and operational definitions, and these results support the continued use of current criteria for RIC regimens until a consensus statement can be developed.

TL;DR: Prochymal can be infused safely into patients with aGVHD and induces response in a high proportion of GVHD patients, and there was no difference with respect to safety or efficacy between the low and high ProChymal dose.

TL;DR: HLA-mismatched/haploidentical HSCT was feasible with unmanipulated blood and bone marrow harvest and was associated with diagnosis of acute leukemia in the high-risk group.

TL;DR: BSI remains a frequent and potentially life-threatening complication of allogeneic HSCT, the causative organism influencing 7- and 30-day mortality rate, and fluoroquinolone-resistance was common, both among GPB and GNR.

TL;DR: Bu-nucleoside analog-based conditioning chemotherapy, thus far represented by fludarabine (Flu), is becoming the conditioning chemotherapy regimen of choice for patients with acute myelogenous leukemia (AML) at many transplant centers.

TL;DR: The issue of whether mixed chimerism post-HCT (which has a higher incidence in RIC transplantation) is associated with increased autoimmune manifestations in patients with WAS remains to be resolved.

TL;DR: In patients with multiple myeloma, prior lenalidomide therapy is associated with failure of stem cell mobilization with filgrastim, and remobilization with chemotherapy and filGrastim is usually successful in these patients.

TL;DR: HBV reactivation is a common late complication among allogeneic HSCT recipients with pretransplant resolved infection and Screening for HBV reactivated should be considered for at-risk HSCT recipient.

TL;DR: It is suggested that blast percentage <5% at HSCT is the major predictor of improved DFS and relapse and prior treatment to reach this disease status may have value in leading toImproved DFS.

TL;DR: The relatively small number of patients and the varying criteria for reporting organ response and dosage reduction of steroids, among other limitations, hinders the ability to reach definitive conclusions on the overall efficacy of rituximab for cGVHD involving other organs.

TL;DR: The data on SCT in ‘‘vulnerable’’ patients, that is, those with HIV infection and elderly patients, is reviewed, and the use of the comorbidity index is discussed and how it can aid in the decision-making process for patients by optimizing.

TL;DR: Low SES, regardless of race, has a negative impact on unrelated donor HCT outcomes and inferior outcomes among African Americans are not fully explained by transplant-related factors or SES.

TL;DR: Patients in the high ferritin group were more likely to die of infection, organ failure, and organ failure and the prognostic impact of pretransplantation serum ferritins in HSCT recipients was emphasized.

TL;DR: Plerixafor and G-CSF increased circulating CD34 cells/microL and led to the adequate collection of stem cells for autotransplant in 96% of the patients, suggesting this combination may have particular value in heavily pretreated patients.

TL;DR: Improved outcomes from early transplantation and immediate availability of CB unit lead us to conclude that CB transplantation is a beneficial option, which should be considered expediently for children with HS.

TL;DR: D dose targeting of busulfan to a narrow therapeutic range was found to increase EFS in children, and adding melphalan to optimal bus sulfuran exposure is associated with a high incidence of toxicity.

TL;DR: Overall, the declines in functioning after HSCT were less pronounced than anticipated, and older patients were not more compromised than younger ones; in multivariate analyses, they reported better overall quality of life and less depression before transplantation.

TL;DR: Clinical studies should be aimed at reducing the incidence of acute graft-versus-host disease (GVHD) and relapse, and dose intensity of the conditioning regimen (RIC versus NST) did not impact outcomes.

TL;DR: An open-labeled, phase III trial was conducted to determine if the addition of infliximab to steroids could improve results for patients with newly diagnosed grade II-IV aGVHD, and found no benefit when compared to corticosteroids alone.

TL;DR: Continuing monitoring and treatment of hypertension and diabetes is necessary in allogeneic HCT survivors, especially in those exposed to high doses of corticosteroids.

TL;DR: Within the first 100 days, the absolute costs of myeloablative and nonmyeloablatives UCB transplantation are higher than myeloabative andnonmyeloabbative MRD transplantation, primarily driven by severe posttransplant complications, graft failure, and prolonged inpatient stay.

TL;DR: Preclinical results support MSC administration as a cell therapy strategy to prevent chronic renal diseases secondary to diabetes and donor cells were found in kidney of DM mice 3 month after transplantation.

TL;DR: The hypotheses for these noninferiority and equivalence research questions are reviewed, power and sample size issues are considered, and how to perform such a test for both binary and survival outcomes are discussed.

TL;DR: It is shown that plerixafor plus G-CSF can safely and effectively remobilize patients with NHL who have failed previous mobilization and common plerxafor-related adverse events included mild gastrointestinal (GI) effects and injection site reactions.

TL;DR: Results support the belief that allogeneic SCT offers a better survival and disease-free outcome versus autologous SCT in MF/SS, likely because of a GVL effect.

TL;DR: LC30 is an independent prognostic factor for transplant outcome in matched unrelated SCT for myelogenous malignancies and is associated with better outcome in patients transplanted from a matched sibling.

TL;DR: In children undergoing allo-BMT, compromised pretransplant lung function is significantly correlated with risk of early respiratory failure but not of overall survival (OS), reductions in lung volumes and diffusion capacity are common 3- to 6-month posttransplant with partial recovery by 12 to 24 months, and there is high mortality following mechanical ventilation, and early PCs are associated with significantly worse OS.

TL;DR: Following remission induction with ATO-based regimens in patients with relapsed APL, consolidation with autologous SCT is associated with a significantly superior clinical outcome compared with ATo- and ATO+ATRA-based maintenance regimens.